{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T13:59:39Z","timestamp":1790431179349,"version":"4.1.0"},"reference-count":83,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2020,9,4]],"date-time":"2020-09-04T00:00:00Z","timestamp":1599177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Sohana Research Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,12,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Combinatorial cell and gene therapies for life-threatening inherited skin disorders have shown tremendous potential for preclinical and clinical implementation with significant progress made for recessive dystrophic epidermolysis bullosa (RDEB). To date, various cell lineages including resident skin cells and adult stem cells have been investigated for gene and cell therapy for RDEB reaching the clinical trial stage.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Sources of data<\/jats:title>\n                  <jats:p>Sources of data are key recent literature, ClinicalTrials.gov, Clinicaltrialsregister.eu and pharma press releases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Areas of agreement<\/jats:title>\n                  <jats:p>Cell-based gene transfer using autologous patients\u2019 cells has demonstrated positive outcomes in preclinical and clinical trials and highlighted the importance of targeting resident skin stem cells to achieve a meaningful long-term effect. Additionally, adult stem cells, such as mesenchymal stromal cells, have the potential to ameliorate systemic manifestations of the disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Areas of controversy<\/jats:title>\n                  <jats:p>While proven safe, the clinical trials of localized treatment have reported only modest and transient improvements. On the other hand, the risks associated with systemic therapies remain high and should be carefully weighed against the potential benefits. It is unclear to what extent adult stem cells can contribute to skin regeneration\/wound healing.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Growing points<\/jats:title>\n                  <jats:p>Further research is warranted in order to fulfil the potential of cellular therapies for RDEB. The development of combinatorial gene and cell-based approaches is required to achieve long-term clinical benefits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Areas timely for developing research<\/jats:title>\n                  <jats:p>Induced pluripotent stem cells can potentially provide a valuable source of autologous patient material for cellular therapies. In addition, recent advances in the field of gene editing can overcome hurdles associated with conventional gene addition approaches.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Data Availability Statement<\/jats:title>\n                  <jats:p>No new data were generated or analysed in support of this review.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bmb\/ldaa029","type":"journal-article","created":{"date-parts":[[2020,8,4]],"date-time":"2020-08-04T19:13:32Z","timestamp":1596568412000},"page":"30-45","source":"Crossref","is-referenced-by-count":11,"title":["Cellular therapy options for genetic skin disorders with a focus on recessive dystrophic epidermolysis bullosa"],"prefix":"10.1093","volume":"136","author":[{"given":"Gaetano","family":"Naso","sequence":"first","affiliation":[{"name":"Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, 30 Guilford street, London WC1N 1EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Petrova","sequence":"additional","affiliation":[{"name":"Molecular and Cellular Immunology Section, UCL Great Ormond Street Institute of Child Health, 30 Guilford street, London WC1N 1EH, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,9,4]]},"reference":[{"key":"2020121509334229200_ref1","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1038\/jid.2009.108","article-title":"Phenotypic and genotypic analyses of genetic skin disease through the online mendelian inheritance in man (OMIM) database","volume":"129","author":"Feramisco","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nature24487","article-title":"Regeneration of the entire human epidermis using transgenic stem cells","volume":"551","author":"Hirsch","year":"2017","journal-title":"Nature"},{"key":"2020121509334229200_ref3","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1001\/jama.2016.15588","article-title":"Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa","volume":"316","author":"Siprashvili","year":"2016","journal-title":"JAMA"},{"key":"2020121509334229200_ref4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/hmg\/6.6.927","article-title":"A model of corrective gene transfer in X-linked ichthyosis","volume":"6","author":"Freiberg","year":"1997","journal-title":"Hum Mol Genet"},{"key":"2020121509334229200_ref5","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1006\/excr.1993.1326","article-title":"Correction of steroid sulfatase deficiency by gene transfer into basal cells of tissue-cultured epidermis from patients with recessive X-linked ichthyosis","volume":"209","author":"Jensen","year":"1993","journal-title":"Exp Cell Res"},{"key":"2020121509334229200_ref6","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1038\/mt.2011.233","article-title":"Preclinical corrective gene transfer in Xeroderma Pigmentosum human skin stem cells","volume":"20","author":"Warrick","year":"2012","journal-title":"Mol Ther"},{"key":"2020121509334229200_ref7","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/mt.2010.201","article-title":"Ex-vivo gene therapy restores LEKTI activity and corrects the architecture of Netherton syndrome-derived skin grafts","volume":"19","author":"Di","year":"2011","journal-title":"Mol Ther"},{"key":"2020121509334229200_ref8","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jdermsci.2010.12.004","article-title":"rAAV2-mediated restoration of LEKTI in LEKTI-deficient cells from Netherton patients","volume":"61","author":"Roedl","year":"2011","journal-title":"J Dermatol Sci"},{"key":"2020121509334229200_ref9","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjd.18128","article-title":"Clinical practice guidelines for laboratory diagnosis of epidermolysis bullosa","volume":"182","author":"Has","year":"2020","journal-title":"Br J Dermatol"},{"key":"2020121509334229200_ref10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jpeds.2007.06.039","article-title":"Cause-specific risks of childhood death in inherited epidermolysis bullosa","volume":"152","author":"Fine","year":"2008","journal-title":"J Pediatr"},{"key":"2020121509334229200_ref11","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00403-003-0444-1","article-title":"Differences in recurrent COL7A1 mutations in dystrophic epidermolysis bullosa: ethnic-specific and worldwide recurrent mutations","volume":"295","author":"Murata","year":"2004","journal-title":"Arch Dermatol Res"},{"key":"2020121509334229200_ref12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.jdermsci.2009.06.015","article-title":"Long-term follow-up of patients with recessive dystrophic epidermolysis bullosa in the Netherlands: expansion of the mutation database and unusual phenotype-genotype correlations","volume":"56","author":"Van den Akker","year":"2009","journal-title":"J Dermatol Sci"},{"key":"2020121509334229200_ref13","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/ng1041","article-title":"Restoration of type VII collagen expression and function in dystrophic epidermolysis bullosa","volume":"32","author":"Chen","year":"2002","journal-title":"Nat Genet"},{"key":"2020121509334229200_ref14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.stemcr.2013.11.001","article-title":"Long-term stability and safety of transgenic cultured epidermal stem cells in gene therapy of junctional epidermolysis bullosa","volume":"2","author":"De Rosa","year":"2014","journal-title":"Stem Cell Reports"},{"key":"2020121509334229200_ref15","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.jaad.2013.08.052","article-title":"Successful therapeutic transplantation of revertant skin in epidermolysis bullosa","volume":"70","author":"Gosty\u0144ski","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2020121509334229200_ref16","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/jid.2013.308","article-title":"Long-term survival of type XVII collagen revertant cells in an animal model of revertant cell therapy","volume":"134","author":"Gosty\u0144ski","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref17","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1126\/scitranslmed.3009342","article-title":"Induced pluripotent stem cells from human revertant keratinocytes for the treatment of epidermolysis bullosa","volume":"6","author":"Umegaki-Arao","year":"2014","journal-title":"Sci Transl Med"},{"key":"2020121509334229200_ref18","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1038\/jid.2013.523","article-title":"Patient-specific naturally gene-reverted induced pluripotent stem cells in recessive dystrophic epidermolysis bullosa","volume":"134","author":"Tolar","year":"2014","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref19","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1056\/NEJMc0809896","article-title":"Revertant mosaicism\u2014patchwork in the skin","volume":"360","author":"Jonkman","year":"2009","journal-title":"N Engl J Med"},{"key":"2020121509334229200_ref20","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/bjd.17943","article-title":"Revertant mosaic fibroblasts in recessive dystrophic epidermolysis bullosa","volume":"181","author":"Twaroski","year":"2019","journal-title":"Br J Dermatol"},{"key":"2020121509334229200_ref21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1038\/nm1504","article-title":"Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells","volume":"12","author":"Mavilio","year":"2006","journal-title":"Nat Med"},{"key":"2020121509334229200_ref22","first-page":"12","article-title":"Toward combined cell and gene therapy for Genodermatoses","volume":"1","author":"De Rosa","year":"2020","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2020121509334229200_ref23","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.celrep.2019.04.055","article-title":"Laminin 332-dependent YAP dysregulation depletes epidermal stem cells in junctional epidermolysis bullosa","volume":"27","author":"De Rosa","year":"2019","journal-title":"Cell Rep"},{"key":"2020121509334229200_ref24","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1038\/mt.2010.91","article-title":"SIN retroviral vectors expressing COL7A1 under human promoters for ex vivo gene therapy of recessive dystrophic epidermolysis bullosa","volume":"18","author":"Titeux","year":"2010","journal-title":"Mol Ther"},{"key":"2020121509334229200_ref25","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/JID.2015.364","article-title":"Lentiviral engineered fibroblasts expressing codon-optimized COL7A1 restore anchoring fibrils in RDEB","volume":"136","author":"Georgiadis","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref26","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1089\/hum.2010.023","article-title":"Long-term type VII collagen restoration to human epidermolysis bullosa skin tissue","volume":"21","author":"Siprashvili","year":"2010","journal-title":"Hum Gene Ther"},{"key":"2020121509334229200_ref27","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1172\/JCI68127","article-title":"Collagen VII plays a dual role in wound healing","volume":"123","author":"Nystr\u00f6m","year":"2013","journal-title":"J Clin Invest"},{"key":"2020121509334229200_ref28","doi-asserted-by":"crossref","first-page":"e130554","DOI":"10.1172\/jci.insight.130554","article-title":"Phase 1\/2a clinical trial of gene-corrected autologous cell therapy for recessive dystrophic epidermolysis bullosa","volume":"4","author":"Eichstadt","year":"2019","journal-title":"JCI Insight"},{"key":"2020121509334229200_ref29","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1038\/jid.2012.11","article-title":"siRNA-mediated allele-specific inhibition of mutant type VII collagen in dominant dystrophic epidermolysis bullosa","volume":"132","author":"Pendaries","year":"2012","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref30","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1038\/sj.jid.5700435","article-title":"Targeted skipping of a single exon harboring a premature termination codon mutation: implications and potential for gene correction therapy for selective dystrophic epidermolysis bullosa patients","volume":"126","author":"Goto","year":"2006","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref31","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1016\/j.jid.2016.07.029","article-title":"Targeted exon skipping restores type VII collagen expression and anchoring fibril formation in an in vivo RDEB model","volume":"136","author":"Turczynski","year":"2016","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref32","first-page":"e379","article-title":"Antisense oligonucleotide-mediated exon skipping as a systemic therapeutic approach for recessive dystrophic epidermolysis bullosa","volume":"5","author":"Bremer","year":"2016","journal-title":"Mol Ther: Nucleic Acids"},{"key":"2020121509334229200_ref33","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.molonc.2013.08.005","article-title":"The design and optimization of RNA trans-splicing molecules for skin cancer therapy","volume":"7","author":"Gruber","year":"2013","journal-title":"Mol Oncol"},{"key":"2020121509334229200_ref34","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/gt.2016.57","article-title":"Construction and validation of an RNA trans-splicing molecule suitable to repair a large number of COL7A1 mutations","volume":"23","author":"Tockner","year":"2016","journal-title":"Gene Ther"},{"key":"2020121509334229200_ref35","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.4049\/jimmunol.179.3.1595","article-title":"Adult human fibroblasts are potent Immunoregulatory cells and functionally equivalent to mesenchymal stem cells","volume":"179","author":"Haniffa","year":"2007","journal-title":"J Immunol"},{"key":"2020121509334229200_ref36","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/sj.jid.5700117","article-title":"Fibroblasts show more potential as target cells than keratinocytes in COL7A1 gene therapy of dystrophic epidermolysis bullosa","volume":"126","author":"Goto","year":"2006","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref37","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1038\/jid.2008.78","article-title":"Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa","volume":"128","author":"Wong","year":"2008","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref38","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1038\/jid.2011.85","article-title":"HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis bullosa","volume":"131","author":"Nagy","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref39","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.jaad.2013.08.014","article-title":"A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa","volume":"69","author":"Venugopal","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"2020121509334229200_ref40","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/bjd.12599","article-title":"Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomized, vehicle-controlled trial","volume":"169","author":"Petrof","year":"2013","journal-title":"Br J Dermatol"},{"key":"2020121509334229200_ref41","doi-asserted-by":"crossref","first-page":"e126243","DOI":"10.1172\/jci.insight.126243","article-title":"Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa","volume":"4","author":"Lwin","year":"2019","journal-title":"JCI Insight"},{"key":"2020121509334229200_ref42","doi-asserted-by":"crossref","first-page":"S100","DOI":"10.1016\/j.jid.2018.03.599","article-title":"591 a phase 1\/2 study of genetically-corrected, collagen VII expressing autologous human dermal fibroblasts injected into the skin of patients with recessive dystrophic epidermolysis bullosa (RDEB)","volume":"138","author":"Marinkovich","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref43","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/bjd.18559","article-title":"EBGene trial: patient preselection outcomes for the European GENEGRAFT ex vivo phase I\/II gene therapy trial for recessive dystrophic epidermolysis bullosa","volume":"182","author":"Gaucher","year":"2020","journal-title":"Br J Dermatol"},{"key":"2020121509334229200_ref44","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/jcp.10260","article-title":"Participation of bone marrow derived cells in cutaneous wound healing","volume":"196","author":"Badiavas","year":"2003","journal-title":"J Cell Physiol"},{"key":"2020121509334229200_ref45","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1182\/blood-2008-06-161299","article-title":"Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cells","volume":"113","author":"Tolar","year":"2009","journal-title":"Blood"},{"key":"2020121509334229200_ref46","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa0910501","article-title":"Bone marrow transplantation for recessive dystrophic epidermolysis bullosa","volume":"363","author":"Wagner","year":"2010","journal-title":"N Engl J Med"},{"key":"2020121509334229200_ref47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.det.2010.01.015","article-title":"Fibroblast-based cell therapy strategy for recessive dystrophic epidermolysis bullosa","volume":"28","author":"Yan","year":"2010","journal-title":"Dermatol Clin"},{"key":"2020121509334229200_ref48","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.jpeds.2015.05.051","article-title":"Reduced toxicity conditioning and allogeneic hematopoietic progenitor cell transplantation for recessive dystrophic epidermolysis bullosa","volume":"167","author":"Geyer","year":"2015","journal-title":"J Pediatr"},{"key":"2020121509334229200_ref49","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2340\/00015555-3097","article-title":"Allogeneic haematopoietic cell transplantation for epidermolysis bullosa: the Dutch experience","volume":"99","author":"Gosty\u0144ska","year":"2019","journal-title":"Acta Derm Venereol"},{"key":"2020121509334229200_ref50","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.jid.2017.12.016","article-title":"EB2017-progress in epidermolysis bullosa research toward treatment and cure","volume":"138","author":"Uitto","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref51","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.4049\/jimmunol.180.4.2581","article-title":"Mesenchymal stem cells are recruited into wounded skin and contribute to wound repair by transdifferentiation into multiple skin cell type","volume":"180","author":"Sasaki","year":"2008","journal-title":"J Immunol"},{"key":"2020121509334229200_ref52","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/mt.2015.58","article-title":"High local concentrations of intradermal MSCs restore skin integrity and facilitate wound healing in dystrophic epidermolysis bullosa","volume":"23","author":"K\u00fchl","year":"2015","journal-title":"Mol Ther"},{"key":"2020121509334229200_ref53","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/blood.V126.23.402.402","article-title":"Mucocutaneous engraftment and type VII collagen (C7) replacement after allogeneic hematopoietic cell transplantation (HCT) in patients with recessive dystrophic epidermolysis bullosa (RDEB)","volume":"126","author":"Tolar","year":"2015","journal-title":"Blood"},{"key":"2020121509334229200_ref54","doi-asserted-by":"crossref","first-page":"14345","DOI":"10.1073\/pnas.1000044107","article-title":"Bone marrow transplantation restores epidermal basement membrane protein expression and rescues epidermolysis bullosa model mice","volume":"107","author":"Fujita","year":"2010","journal-title":"Proc Natl Acad Sci"},{"key":"2020121509334229200_ref55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/14653249.2010.518609","article-title":"Gene expression signatures of mouse bone marrow-derived mesenchymal stem cells in the cutaneous environment and therapeutic implications for blistering skin disorder","volume":"13","author":"Alexeev","year":"2011","journal-title":"Cytotherapy"},{"key":"2020121509334229200_ref56","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3324\/haematol.13699","article-title":"Mesenchymal stem cells: the fibroblasts\u2019 new clothes?","volume":"94","author":"Haniffa","year":"2009","journal-title":"Haematologica"},{"key":"2020121509334229200_ref57","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/14653241003587637","article-title":"Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa","volume":"12","author":"Conget","year":"2010","journal-title":"Cytotherapy"},{"key":"2020121509334229200_ref58","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1038\/jid.2015.158","article-title":"Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa","volume":"135","author":"Petrof","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref59","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/dth.12305","article-title":"Treatment of dystrophic epidermolysis bullosa with bone marrow non-hematopoeitic stem cells: a randomized controlled trial","volume":"29","author":"El-Darouti","year":"2016","journal-title":"Dermatol Ther"},{"key":"2020121509334229200_ref60","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/labinvest.2017.85","article-title":"Rapid generation of Col7a1 mouse model of recessive dystrophic epidermolysis bullosa and partial rescue via immunosuppressive dermal mesenchymal stem cells","volume":"97","author":"Webber","year":"2017","journal-title":"Lab Invest"},{"key":"2020121509334229200_ref61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jid.2019.05.031","article-title":"Human mesenchymal stromal cells engineered to express collagen VII can restore anchoring fibrils in recessive dystrophic epidermolysis bullosa skin graft chimeras","volume":"140","author":"Petrova","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref62","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1016\/j.jid.2018.04.028","article-title":"Intradermal injection of bone marrow mesenchymal stromal cells corrects recessive dystrophic epidermolysis bullosa in a xenograft model","volume":"138","author":"Ganier","year":"2018","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref63","doi-asserted-by":"crossref","first-page":"6609","DOI":"10.1073\/pnas.1016753108","article-title":"PDGFRalpha-positive cells in bone marrow are mobilized by high mobility group box 1 (HMGB1) to regenerate injured epithelia","volume":"108","author":"Tamai","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020121509334229200_ref64","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/scrt511","article-title":"Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa","volume":"5","author":"Perdoni","year":"2014","journal-title":"Stem Cell Res Ther"},{"key":"2020121509334229200_ref65","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaad.2019.11.038","article-title":"Phase I\/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa","author":"Rashidghamat","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2020121509334229200_ref66","doi-asserted-by":"crossref","first-page":"8797","DOI":"10.1073\/pnas.1100332108","article-title":"Generation of keratinocytes from normal and recessive dystrophic epidermolysis bullosa-induced pluripotent stem cells","volume":"108","author":"Itoh","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020121509334229200_ref67","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/jid.2010.364","article-title":"Differentiation of mouse induced pluripotent stem cells into a multipotent keratinocyte lineage","volume":"131","author":"Bilousova","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref68","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/jid.2010.346","article-title":"Induced pluripotent stem cells from individuals with recessive dystrophic epidermolysis bullosa","volume":"131","author":"Tolar","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref69","doi-asserted-by":"crossref","first-page":"16014","DOI":"10.1038\/npjregenmed.2016.14","article-title":"CRISPR\/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa","volume":"1","author":"Webber","year":"2016","journal-title":"NPJ Regen Med"},{"key":"2020121509334229200_ref70","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1073\/pnas.1512028113","article-title":"Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa","volume":"113","author":"Shinkuma","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020121509334229200_ref71","doi-asserted-by":"crossref","first-page":"26846","DOI":"10.1073\/pnas.1907081116","article-title":"CRISPR\/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells","volume":"116","author":"Jack\u00f3w","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020121509334229200_ref72","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mt.2013.56","article-title":"TALEN-based gene correction for epidermolysis bullosa","volume":"21","author":"Osborn","year":"2013","journal-title":"Mol Ther"},{"key":"2020121509334229200_ref73","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1042\/ETLS20180148","article-title":"CRISPR\/Cas9 gene editing for genodermatoses: progress and perspectives","volume":"3","author":"Naso","year":"2019","journal-title":"Emerg Top Life Sci"},{"key":"2020121509334229200_ref74","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1016\/j.ymthe.2017.07.005","article-title":"COL7A1 editing via CRISPR\/Cas9 in recessive dystrophic epidermolysis bullosa","volume":"25","author":"Hainzl","year":"2017","journal-title":"Mol Ther"},{"key":"2020121509334229200_ref75","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","article-title":"Ex vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR\/Cas9 and homology-directed repair","volume":"12","author":"Izmiryan","year":"2018","journal-title":"Mol Ther Nucleic Acids"},{"key":"2020121509334229200_ref76","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1073\/pnas.1614775114","article-title":"Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model","volume":"114","author":"Wu","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2020121509334229200_ref77","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ymthe.2019.03.007","article-title":"Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR\/Cas9-mediated gene editing","volume":"27","author":"Bonafont","year":"2019","journal-title":"Mol Ther"},{"key":"2020121509334229200_ref78","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/nature17946","article-title":"Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage","volume":"533","author":"Komor","year":"2016","journal-title":"Nature"},{"key":"2020121509334229200_ref79","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nature24644","article-title":"Programmable base editing of A-T to G-C in genomic DNA without DNA cleavage","volume":"551","author":"Gaudelli","year":"2017","journal-title":"Nature"},{"key":"2020121509334229200_ref80","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jid.2019.07.701","article-title":"Base editor correction of COL7A1 in recessive dystrophic epidermolysis bullosa patient-derived fibroblasts and iPSCs","volume":"140","author":"Osborn","year":"2020","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref81","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1056\/NEJMoa0905955","article-title":"Limbal stem-cell therapy and long-term corneal regeneration","volume":"363","author":"Rama","year":"2010","journal-title":"N Engl J Med"},{"key":"2020121509334229200_ref82","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1038\/jid.2013.10","article-title":"Intravenously injected recombinant human type VII collagen homes to skin wounds and restores skin integrity of dystrophic epidermolysis bullosa","volume":"133","author":"Woodley","year":"2013","journal-title":"J Invest Dermatol"},{"key":"2020121509334229200_ref83","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm1063","article-title":"Injection of recombinant human type VII collagen restores collagen function in dystrophic epidermolysis bullosa","volume":"10","author":"Woodley","year":"2004","journal-title":"Nat Med"}],"container-title":["British Medical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/136\/1\/30\/34903674\/ldaa029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bmb\/article-pdf\/136\/1\/30\/34903674\/ldaa029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T15:22:02Z","timestamp":1608045722000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bmb\/article\/136\/1\/30\/5901489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,4]]},"references-count":83,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,9,4]]},"published-print":{"date-parts":[[2020,12,15]]}},"URL":"https:\/\/doi.org\/10.1093\/bmb\/ldaa029","relation":{},"ISSN":["0007-1420","1471-8391"],"issn-type":[{"value":"0007-1420","type":"print"},{"value":"1471-8391","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,12]]},"published":{"date-parts":[[2020,9,4]]}}}